spacer
home > ebr > summer 2017 > hidden treasures
PUBLICATIONS
European Biopharmaceutical Review

Hidden Treasures

Nowadays, both the EMA and FDA want to see treatments based on solid evidence, but how can we document this? For many different diseases, therapeutic effects seem to be poorly defined and challenging to monitor. Fighting a symptom, such as lowering the body’s temperature during a fever, does not count. Truly desirable effects that should be assessed or monitored would include killing bad bacteria in case of an infection, thus lowering the body’s bacterial load.

Usual Matrix Used

Each individual biomarker is part of one or more of seven categories, as defined by the FDA and National Institutes of Health Working Group, including diagnostic, monitoring, prognostic and safety. Biomarkers are endogenous substances, usually easiest to determine in blood plasma, saliva or urine. These bodily fluids are not difficult to obtain and derived from or connected to the bloodstream, which nourishes all organs and is also in contact with the central nervous system and the cerebrospinal fluid. This blood-brain barrier protects our control centre from the detrimental influences of a great number of large molecular substances, which are not able to cross it.

Historically, many may first think of protein biomarkers. Proteins may indeed be closer to the body’s reaction to a disease than small molecules. However, detecting these specific proteins in the blood is not always easy. We have many thousands of proteins in the body which consist of amino acids, and the sequence of the connected amino acids is responsible for the function of the protein.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Professor Hermann Mascher, founder and Bioanalytical Consultant at pharm-analyt Labor, has more than 100 publications in peer-reviewed journals, including two books by Wiley-VCH. He is also the inventor of three patents for biomarkers in the area of rare lysosomal storage diseases: Gaucher, NPC and metachromatic leukodystrophy.
spacer
Professor Hermann Mascher
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

NEUWAY Pharma and Cobra Biologics collaborate to develop GMP grade Engineered Protein Capsules (EPCs) manufacturing process

International CDMO of biologics and pharmaceuticals, together with a biopharma company developing drugs for orphan diseases, announce the conclusion of a Service Agreement relating to Engineered Protein Capsules
More info >>

White Papers

Advanced BioDesign Outlines Solutions

Advanced BioDesign

Launching an immunisation programme is an important experimental step that needs care. With Advanced BioDesign, clients may develop and produce antibodies according to customers' specific needs. The company offers: real support and advice from a dedicated team all along your project; large and modern SPF animal facility; ethical treatment of animals. The evaluation of a project is free-of-charge and with no obligation. Dedicated project managers will work with clients from the beginning to the end of a custom antibody project to ensure the highest level of quality and service.
More info >>

 
Industry Events

BIO-Europe® 2017

6-8 November 2017, Messedamm 26 14055 Berlin Germany

The 23rd annual BIO-Europe® event is the largest biotechnology partnering conference held in Europe. Over 3,800 global decision makers from biotechnology, pharma and finance annually attend BIO-Europe to identify new business opportunities and develop strategic relationships. Business development executives and dealmakers consider BIO-Europe a must-attend event and an effective business strategy enabling them to meet and present to numerous potential partners. BIO-Europe features the industry’s most advanced web-based partnering system enabling delegates from all parts of the biotechnology value chain to quickly identify, engage and enter into strategic relationships that drive their business successfully forward. BIO-Europe's world-class workshops, panels and active exhibition along with thousands of prescheduled one-to-one meetings make this event an unrivaled forum for companies across the biotech value chain to meet and do business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement